What is Microgen?
Microgen Laboratories is at the forefront of developing rapid, user-friendly, and cost-effective pathogen detection kits. Their innovative solutions are designed to swiftly identify a range of viruses, bacteria, and fungi across diverse environments. With a strategic focus on critical public health concerns such as CMV, HSV, and syphilis, Microgen aims to equip healthcare providers and researchers with efficient diagnostic tools. This commitment to improving patient outcomes and reducing healthcare expenditures positions Microgen as a key player in the infectious disease diagnostics market.
How much funding has Microgen raised?
Microgen has raised a total of $25K across 1 funding round:
Debt
$25K
Debt (2021): $25K with participation from PPP
What's next for Microgen?
The recent influx of substantial expansion capital, indicated by the $25K round, signals Microgen's strategic intent to scale operations and potentially broaden its product portfolio or market reach. As a company operating at a significant Series B/C stage, this investment is likely earmarked for accelerating research and development, enhancing manufacturing capabilities, and expanding its commercial footprint. The focus on critical pathogen detection suggests a trajectory towards becoming a leading provider of diagnostic solutions for healthcare systems and research institutions globally.
See full Microgen company page
